Immunotherapy-Related Diabetes in Melanoma: A Management Perspective
Source: OncLive, February 2024
Afreen Shariff, MD, MBBS, discusses managing immunotherapy-related diabetes in melanoma, emphasizing the critical need to detect sudden changes in blood sugar levels and advocating for a multidisciplinary approach.
This is a video synopsis/summary of an OncLive Insights® involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.
Khushalani asks Shariff how often she consults endocrinology for immunotherapy-induced type 1 diabetes (T1D) and when it should be done. She states
T1D occurs in?less than 1% of immunotherapy-treated patients, but she sees many cases. The key is recognizing abrupt hyperglycemia without recent steroids or type 2 diabetes history. Endocrinology should be urgently consulted to start insulin and avoid diabetic ketoacidosis given complete ?-cell destruction.